182 related articles for article (PubMed ID: 2452469)
21. [Biohumeral markers in the diagnosis of pancreatic carcinoma].
Panucci A; Del Favero G; Falmis C; Brosolo P; Basso D; Pedrazzoli S; Baccaglini U; Marchioro L; Bonvilini P; Naccarato R
Recenti Prog Med; 1985; 76(7-8):385-91. PubMed ID: 3865269
[No Abstract] [Full Text] [Related]
22. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
Klapdor R; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
[No Abstract] [Full Text] [Related]
23. [Comparative study with reduction rate of tumor and decrease rate of tumor markers as an effect of MMC on human cancer producing CEA and CA19-9 xenotransplanted in nude mice].
Takahashi Y; Ohta T; Mai M
Nihon Geka Gakkai Zasshi; 1987 Apr; 88(4):502. PubMed ID: 3108655
[No Abstract] [Full Text] [Related]
24. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
25. [Tumour markers of pancreatic cancer (tumour associated antigens)].
Groblewska M; Mroczko B; Szmitkowski M
Pol Arch Med Wewn; 2005 Jun; 113(6):585-93. PubMed ID: 16454450
[No Abstract] [Full Text] [Related]
26. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer.
Kiriyama S; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Ono H; Sakai Y
Cancer; 1990 Apr; 65(7):1557-61. PubMed ID: 2311067
[TBL] [Abstract][Full Text] [Related]
27. [Studies on the methods of diagnosing pancreatic cancer with the use of tumor markers by discriminant analysis].
Kawanishi M; Fujita S; Kunita S; Furukawa Y; Yamada H; Nakamura M; Kajiyama G
Nihon Shokakibyo Gakkai Zasshi; 1985 Jul; 82(7):1731-41. PubMed ID: 3878419
[No Abstract] [Full Text] [Related]
28. Biochemical and immunologic diagnosis of cancer. Lung cancer.
Schwartz MK
Tumour Biol; 1987; 8(2-3):134-8. PubMed ID: 2834814
[No Abstract] [Full Text] [Related]
29. [Use of radioimmunoanalysis of tumor markers in the diagnosis of carcinoma of the breast, ovary and intestines].
Kausitz J
Bratisl Lek Listy; 1988 Aug; 89(8):563-76. PubMed ID: 3179762
[No Abstract] [Full Text] [Related]
30. Noninvasive diagnosis of advanced pancreatic cancer by real-time ultrasonography, carcinoembryonic antigen, and carbohydrate antigen 19-9.
Wang TH; Lin JT; Chen DS; Sheu JC; Sung JL
Pancreas; 1986; 1(3):219-23. PubMed ID: 3554223
[TBL] [Abstract][Full Text] [Related]
31. [Clinical utility of tumor markers in gastric and colon cancer].
Ogawa K; Naritaka Y; Koyama N; Ohtani Y; Kawata H; Yagawa H; Kajiwara T; Sakakibara N
Gan No Rinsho; 1985 May; 31(6 Suppl):638-47. PubMed ID: 3861884
[TBL] [Abstract][Full Text] [Related]
32. [Tumor markers in gastrointestinal cancer and its clinical significance].
Taguchi T; Ota J; Sumida S; Rii M
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3004-9. PubMed ID: 3479051
[TBL] [Abstract][Full Text] [Related]
33. [Oncofetal antigen].
Nishida K; Yoshikawa T; Kondo M
Nihon Rinsho; 1980; 38(1):152-60. PubMed ID: 6156250
[No Abstract] [Full Text] [Related]
34. [Antigens associated with cancer of the pancreas].
Burtin P
Bull Cancer; 1990; 77(1):69-73. PubMed ID: 2317577
[TBL] [Abstract][Full Text] [Related]
35. [The relation between serum carcinoembryonic antigens (CEA) and response to chemotherapy in patients with advanced gastric cancer].
Saito D; Yoshida S; Hijikata A; Tajiri H; Yamaguchi H; Yoshimori M; Ohkura H; Okazaki N; Yoshida T; Yoshino M
Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):948-57. PubMed ID: 3480325
[No Abstract] [Full Text] [Related]
36. [Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen in gastrointestinal neoplasms. Comparison of markers].
Capocasale E; Contini S; Rossetti A; Del Sante G; Gregori G
Acta Biomed Ateneo Parmense; 1985; 56(6):231-6. PubMed ID: 2940782
[TBL] [Abstract][Full Text] [Related]
37. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
38. A clinical evaluation of various tumor markers for the diagnosis of pancreatic cancer.
Satake K; Chung YS; Yokomatsu H; Nakata B; Tanaka H; Sawada T; Nishiwaki H; Umeyama K
Int J Pancreatol; 1990; 7(1-3):25-36. PubMed ID: 2081926
[TBL] [Abstract][Full Text] [Related]
39. [Value and limitations of neoplasm markers in the diagnosis of pancreatic carcinoma].
Fabris C; Basso D; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Ferrara C; Scalon P; Naccarato R
Recenti Prog Med; 1991 Mar; 82(3):166-72. PubMed ID: 2047559
[TBL] [Abstract][Full Text] [Related]
40. [Fundamental and clinical evaluation of ELSA CA 72-4 kit for serum CA 72-4 antigen].
Omori S; Murakami M; Fukuchi M
Kaku Igaku; 1990 Jun; 27(6):667-75. PubMed ID: 2214330
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
